Verkkokauppa.com Oyj - Managers' Transactions - Seikku
- 12
Verkkokauppa.com Oyj MANAGERS' TRANSACTIONS February 21, 2019 at 9:15
Managers' Transactions
Transaction notification under Article 19 of EU Market Abuse Regulation.
Person subject to the notification requirement
Name: Seikku, Kai
Position: Member of the Board
____________________________________________
Issuer: Verkkokauppa.com Oyj
LEI: 743700QZE6B52SHHTV75
Notification type: INITIAL NOTIFICATION
Reference number: 743700QZE6B52SHHTV75_20190220141236_5
____________________________________________
Transaction date: 2019-02-20
Instrument type: SHARE
ISIN: FI4000049812
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION
Transaction details
(1): Volume: 1,067 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 1,067 Volume weighted average price: 0 EUR
For more information:
Panu Porkka, CEO
[email protected]
Tel. +358 10 309 5555
Jussi Tallgren, CFO
[email protected]
Tel. +358 10 309 5555
Certified Adviser
Nordea Bank Oyj
Tel. +358 9 5300 6785
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.verkkokauppa.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verkkokauppa.com Oyj via Globenewswire
GlobeNewswire Europe, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
- GXO Announces Launch of Senior Notes Offering
- EQS-News: Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
- Form 8.3 - The Vanguard Group, Inc.: Redrow PLC
- Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
- Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp